Generics News
Generics
India-based Natco Pharma has announced the acquisition of a 35.75% stake in Adcock Ingram, a 135-year-old South African pharmaceutical giant, in a deal valued at approximately $226 million. 13 October 2025
Generics
Private equity firm GTCR has bought Czech Republic-based generics company Zentiva for a reported 4.1 billion euros ($4.8 billion) from prior owner Advent. 12 September 2025
Generics
Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a generic version of Saxenda (liraglutide injection). 1 September 2025
Most Read
Companies, Mergers & Acquisitions
Company Spotlight
Recent news
Generics
UK specialty generics company Aspire Pharma has acquired Caragen, an Ireland-based pharmaceutical organization with a strong presence in hospital immunology therapies. 11 February 2026
Generics
Danish drugmaker's Novo Nordisk’s shares fell more than 8% on Thursday after Hims & Hers announced that it would be releasing a compounded version of its oral GLP-1 agonist Wegovy (semaglutide), a weight-loss pill with a $49-a-month introductory price. 6 February 2026
Generics
Indian drugmaker Lupin has launched topiramate extended-release capsules in the USA after receiving approval from the US Food and Drug Administration. 5 February 2026
Generics
US generics lobby the Association for Accessible Medicines (AAM) has welcomed passage of Q1/Q2 provisions in recent US funding legislation, arguing they will speed access to lower-cost medicines. 4 February 2026
Generics
A group of 42 US states and territories has filed a fresh antitrust lawsuit accusing Swiss pharma Novartis and its former generics unit Sandoz of colluding to fix prices and allocate markets for generic medicines over several years. 4 February 2026
Refine search
In Brief
Generics
10 February 2026 Japan’s Astellas Pharma announced that it has reached an agreement with Lupin Limited and Lupin Pharmaceuticals to settle pending US patent litigation regarding Astellas’ Myrbetriq (mirabegron), a treatment for overactive bladder (OAB).
Generics
18 November 2025 India’s Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) for diroximel fumarate delayed-release capsules, 231mg (Biogen’s Vumerity delayed-release capsules, 231mg).
Insights
Generics
For decades, the generics industry has been dedicated to supporting the financial sustainability of health systems. By delivering high-quality, affordable alternatives at scale, generics have helped protect treatment access and enabled health services to meet growing demand without compromising standards of care. 11 December 2025
Generics
India’s pharmaceutical recalls are drawing global attention, as the US Food and Drug Administration (FDA) recently announced a nationwide recall of over 140,000 bottles of Indian-made atorvastatin, a widely prescribed cholesterol-lowering drug. 1 December 2025
Generics
The Russian drugmaker Akselpharm has successfully defended its patent for osimertinib the active ingredient of UK pharma major AstraZeneca’s in the Russian court, reports The Pharma Letter’s local correspondent. 24 November 2025
Generics
India’s GLP-1 drug market is poised for explosive growth, outpacing global trends and positioning domestic pharma giants to challenge multinational dominance. 3 November 2025
Generics
In a strategic move to rebalance trade with India, Russian President Vladimir Putin has directed his government to ramp up imports of Indian pharmaceuticals and agricultural products.
With pharmaceuticals already representing a $5 billion surplus in India’s favor, the Kremlin’s push signals a major opportunity for Indian drugmakers to expand their footprint in Russia’s pharmaceutical market, reports The Pharma Letter’s India correspondent. 6 October 2025
Generics
In a move reminiscent of past trade disputes, China appears to have launched a price war on key active pharmaceutical ingredients (APIs), directly challenging India's push for self-reliance in the pharmaceutical sector. 18 September 2025
Generics
India’s pharmaceutical sector continues to assert its dominance on the global stage, driven by a surge in generic drug launches that are reshaping access to affordable healthcare. A flurry of filings and approvals are turning India’s pharma sector into a hotbed of innovation and investment, reports The Pharma Letter’s India correspondent. 8 August 2025
Boardroom
The board of directors of the USA’s Association for Accessible Medicines (AAM) has elected Bob Hoffman as chairman. Mr Hoffman, chief commercial officer of US generics for Lupin Pharmaceuticals, most recently served as vice chairman of the AAM board for the past two terms. 30 January 2026
Effective January1, 2026, STADA Arzneimitel’s global head of communications, Frank Staud, is additionally assuming global responsibility for STADA’s global government affairs, the German generics and consumer healthcare major announced today. 16 January 2026
Paul Burden has been appointed associate vice president and country head of Accord UK, effective immediately. 5 January 2026
German generics and consumer healthcare major STADA Arzneimittel has appointed Craig Shaw as its general manager in the UK. 14 November 2025
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze